Theravance Biopharma (TBPH) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Theravance Biopharma (TBPH) over the last 12 years, with Q4 2024 value amounting to $22.4 million.
- Theravance Biopharma's Accumulated Depreciation & Amortization rose 379.48% to $22.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $22.4 million, marking a year-over-year increase of 379.48%. This contributed to the annual value of $22.4 million for FY2024, which is 379.48% up from last year.
- Per Theravance Biopharma's latest filing, its Accumulated Depreciation & Amortization stood at $22.4 million for Q4 2024, which was up 379.48% from $21.6 million recorded in Q4 2023.
- Theravance Biopharma's 5-year Accumulated Depreciation & Amortization high stood at $45.8 million for Q4 2020, and its period low was $21.6 million during Q4 2023.
- Over the past 5 years, Theravance Biopharma's median Accumulated Depreciation & Amortization value was $32.8 million (recorded in 2022), while the average stood at $32.2 million.
- As far as peak fluctuations go, Theravance Biopharma's Accumulated Depreciation & Amortization tumbled by 3427.34% in 2023, and later surged by 379.48% in 2024.
- Over the past 5 years, Theravance Biopharma's Accumulated Depreciation & Amortization (Quarter) stood at $45.8 million in 2020, then decreased by 15.97% to $38.5 million in 2021, then dropped by 14.69% to $32.8 million in 2022, then plummeted by 34.27% to $21.6 million in 2023, then increased by 3.79% to $22.4 million in 2024.
- Its last three reported values are $22.4 million in Q4 2024, $21.6 million for Q4 2023, and $32.8 million during Q4 2022.